Rhythm Prelim Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements

 -- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 --

-- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 --

-- Completed enrollment in supplemental Japanese cohort of Phase 3 trial of setmelanotide in acquired hypothalamic obesity --

-- Completed enrollment in two substudies in Phase 3 EMANATE trial of setmelanotide in genetically-caused MC4R pathway diseases --

-- Plan to initiate new Phase 2 trial exploring setmelanotide in Prader-Willi syndrome --

https://www.globenewswire.com/news-release/2025/01/10/3007577/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2024-Net-Product-Revenues-Pipeline-Advancements-and-Upcoming-Milestones.html